In addition, FGFR4 may be constitutively-activated or overexpressed in a variety of human neoplasias, including hepatocellular carcinoma [54], [55], prostate cancer [9], [56], rhabdomyosarcoma [57] and breast cancer [58], [59], and the potential utility of FGF19 and/or FGFR4 as a target for growth inhibition has been proposed [54], [60], [61]. The gene discussed is FGF19; the disease is rhabdomyosarcoma.